Banner Witcoff’s Mercedes Meyer, Ph.D., will join the “Spotlight on Antibody Patent Prosecution in the EU and the US” panel at the C5 Pharma & Biotech Patent Litigation in Europe on May 19 in Amsterdam.
The session will address the evolving landscape of antibody patenting in Europe and the U.S., incorporating crucial case law developments into effective prosecution strategies. Mercedes and her co-panelists will analyze recent influential decisions and explore their implications for drafting and litigating antibody patents in different jurisdictions.
Topics of discussion will include:
- Adopting effective strategies for claiming antibodies, considering different patent office interpretations and how to draft claims that secure protection across jurisdictions
- Comparing the EU and US approaches to sufficiency and inventive step
- Examining how recent EPO decisions influence the acceptability of claims where a combination of antigen plus function is used to define an antibody
- Understanding the prosecution takeaways for broad claims from the US perspective, including the takeaways from the U.S. Supreme Court’s decision, which deemed claims of two Amgen patents invalid due to insufficient enablement for a genus of antibodies
- Understanding the nuances of epitope-based claims, functional antibody claims, combination therapies, and defining cell therapy products
Read more about the event by clicking here.
